What we are studying
The purpose of this study is to learn more about amyotrophic lateral sclerosis (ALS) and other related neurodegenerative diseases, including frontotemporal dementia (FTD), primary lateral sclerosis (PLS), hereditary spastic paraplegia (HSP), progressive muscular atrophy (PMA) and multisystem proteinopathy (MSP). More precisely, we want to identify the links that exist between the disease phenotype (phenotype
refers to observable signs and symptoms) and the disease genotype (genotype refers to your genetic information). We also want to identify biomarkers of ALS and related diseases. A biomarker is an indicator of the disease that can easily be measured. Our long-term goal is to use this information to advance the development of therapies for this group of neurodegenerative disorders.
You are eligible to participate in the study for one of the following reasons:
1) you have ALS or a related disease, or
2) you have a family member affected with ALS or a related disease who is already taking part in the study.
ALS or related-disorder patients will be paid $40 for each of the five scheduled in person study visits. Subjects may be paid up to $240 in total since there are 5 in-person visits scheduled and one additional visit may be required.